Lineage Cell Therapeutics, Inc. (LCTX)

Biological Products, (No Diagnostic Substances) · market cap $248M · as of 2026-07-10

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-05 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Lineage Cell Therapeutics (LCTX) is a clinical-stage cell therapy company with ~70 employees and a $334M market cap at $1.34/share. Its lead asset, AST-OPC1, is in Phase 2 for cervical spinal cord injury, a high-unmet-need indication with no approved regenerative therapies. With $35.9M cash and ~13 months of runway, the company faces near-term financing pressure ahead of any meaningful data readout.

The catalyst path

2026-11-05 (est.)Earningsimp 5/10
2026-12-31Data Readoutimp 4/10

Pipeline

Asset	Phase	Indication
AST-OPC1	Phase 2	Cervical Spinal Cord Injury

Price & technical context

3-month

-33.3%

6-month

-43.4%

12-month

-46.7%

52-wk range

$0.90–$1.96

vs 50-day MA

-15.4%

vs 200-day MA

-35.8%

Realized vol

54.6%

Max drawdown

-58.9%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for LCTX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.